TORONTO, Oct. 22 /CNW/ -- Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received approval in Canada to manufacture and market RAN(R)-Lisinopril 5, 10 and 20 mg oral tablets from Health Canada, Therapeutic Products Directorate (TPD). Total brand market for Lisinopril 5, 10, and 20 mg oral tablets in Canada is CAD $46 mil. (IMS-MAT: August 2007).
